Early discharge after intensive AML, MDS chemo can reduce costs, antibiotics use
the ONA take:
Early discharge following intensive acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) can reduce costs and use of intravenous antibiotics, according to a new study published online ahead of print in JAMA Oncology.
Because adults with AML or MDS typically remain hospitalized after induction or salvage chemotherapy, health care costs are driven up by the prolonged inpatient stay. Researchers sought to evaluate whether early discharge and outpatient management would be safe and reduce costs for these patients.
For the study, researchers from the University of Washington and Fred Hutchinson Cancer Research Center in Seattle enrolled 146 patients with AML or MDS. Of those, 107 were discharged early and 29 served as inpatient controls. The early discharge patients were released from the hospital at the completion of chemotherapy and were provided with supportive care in the outpatient setting.
Results showed no significant difference in intensive care unit (ICU) days or transfusions per study day between the two treatment arms. Early discharge patients had more positive blood cultures than the inpatient controls but required fewer intravenous antibiotics. Costs were also lower for the early discharge group than for inpatients but had increased costs per inpatient day when readmitted for complications.
Outpatient Management Following Intensive AML or MDS Chemotherapy
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|